E. coli H7 Flagella Immunogen for Bovine Vaccine
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of an effective vaccine to prevent or reduce colonization of Shiga toxin-producing Escherichia coli (EHEC) in bovines, specifically EHEC O157:H7, which poses a risk of food contamination and animal health issues.
Innovation Solution
The use of E. coli H7 protein, particularly from EHEC O157:H7, as an immunogen to induce a mucosal immune response and reduce bacterial colonization, administered parenterally, either alone or as a fusion protein to enhance immune response, to bovines to prevent EHEC colonization and shedding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a vaccine is developed to prevent EHEC colonization in bovines, then animal health and food safety are improved, but there is currently no effective vaccine available
Solution Approach 1:
The patent extracts the H7 flagella protein from the complete E. coli O157:H7 bacterium to create a purified subunit vaccine. This extraction approach isolates the specific virulence factor (flagella) responsible for intestinal colonization, enabling vaccine development without using the entire pathogen, thus improving safety while maintaining effectiveness.
Solution Approach 2:
The vaccine targets the specific H7 flagella antigen rather than attempting to protect against all E. coli serotypes. This localized approach focuses immunogenicity on the critical colonization factor, creating a specialized vaccine that addresses the specific threat of EHEC O157:H7 intestinal attachment.
2Reliability
If H7 protein is administered parenterally to induce mucosal immune response, then immune protection is achieved, but the route of administration differs from traditional oral vaccine approaches
Solution Approach 1:
Instead of administering the vaccine orally (the conventional route for inducing mucosal immunity), the patent inverts the approach by using parenteral administration (injection). This unexpected route achieves mucosal protection through systemic immune activation, demonstrating an innovative deviation from traditional vaccine delivery methods.
Solution Approach 2:
The H7 flagella protein serves as an intermediary that, when introduced parenterally, triggers a systemic immune response that subsequently provides mucosal protection. The protein acts as a mediator between the parenteral administration route and the desired mucosal immune outcome, bridging the gap between injection and gut immunity.
3Reliability
If H7 is used as a fusion protein, then immune response is enhanced, but the protein structure becomes more complex
Solution Approach 1:
The patent merges the H7 flagella protein with another protein to create a fusion protein. This combination consolidates the immunogenic properties of H7 with additional antigenic elements, producing a enhanced immune response through the synergistic effect of multiple antigens presented in a single molecular structure.
Solution Approach 2:
The fusion protein represents a composite antigen structure combining H7 flagella sequences with additional protein elements. This composite approach leverages the immunogenicity of multiple components within a single chimeric protein, creating a more potent vaccine antigen that elicits stronger and broader immune responses.
Data Source
Figure 1A~1F
Figure 2
Figure 3~4B
AI summary
Immunogenic compositions containing Escherichia coli O157:H7 flagella including fusion proteins and methods using the immunogenic compositions are disclosed. Including an immune response in an animal to to Escherichia coli O157:H7 flagella will result in prevention of colonization by Escherichia coli O157:H7 in the animal or a reduction in the amount of Escherichia coli O157:H7 infecting the animal. The immune composition will prevent or reduce the attachment of Escherichia coli O157:H7 to cells within the animal.